BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

BACKGROUND: Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher response rates in patients with cancer. Immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandel, Ilana, Haves Ziv, Dana, Goldshtein, Ilana, Peretz, Tsuri, Alishekevitz, Dror, Fridman Dror, Anna, Hakim, Motti, Hashmueli, Sharon, Friedman, Itay, Sapir, Yair, Greco, Rita, Qu, Hongjing, Nestle, Frank, Wiederschain, Dmitri, Pao, Lily, Sharma, Sharad, Ben Moshe, Tehila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472153/
https://www.ncbi.nlm.nih.gov/pubmed/36096532
http://dx.doi.org/10.1136/jitc-2022-004859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472153/
https://www.ncbi.nlm.nih.gov/pubmed/36096532
http://dx.doi.org/10.1136/jitc-2022-004859

Ejemplares similares